Skip to content
Companies

Pluristyx

Stem cell lines and manufacturing for cell therapy makers

Raised to date

$9.8M

of $14.8M offered across 1 Form D filing

Still open
$5M
Investors
13
Last filed
Jul 13, 2026

About

Pluristyx is a Seattle-based biotechnology company supplying induced pluripotent stem cell (iPSC) products and manufacturing services for cell and gene therapy developers. It sells research- and clinical-grade iPSC lines and banks, culture and cryopreservation kits, differentiated cells, and custom cell lines, and provides gene editing, process development, and GMP manufacturing. Its proprietary engineering technologies include the FailSafe safety switch and iACT Stealth Cells immune-evasion package for allogeneic therapies. The company operates sites in Seattle, Washington and Toronto, Canada.

Combines off-the-shelf clinical-grade iPSC banks with proprietary gene-editing technologies (FailSafe safety switch, iACT Stealth immune cloaking), which the company says lets clients reach GMP edited iPSC banks in about 18 months with a large reduction in development timelines.

Funding

  • EquityFiled Jul 13, 2026Form D
    $9.8M/ $14.8M

Product

Pluristyx iPSC platform

Cell therapy raw materials and contract development

An integrated platform of ready-to-use and custom induced pluripotent stem cell products backed by gene editing and GMP manufacturing, spanning PluriBank iPSC banks, PluriKit and PluriFreeze culture and cryopreservation products, custom iPSC lines, and differentiated cells.

  • Research-grade and clinical/GMP-grade iPSC cell banks (PluriBank)
  • FailSafe safety switch for engineered cell products
  • IACT Stealth Cells immune-evasion engineering for allogeneic therapies

Built for

Pharmaceutical and biotechnology companies developing allogeneic cell and gene therapies, plus academic and non-profit regenerative medicine research groups

People on file